brand logo

Am Fam Physician. 2006;73(8):1437-1438


Ramelteon (Rozerem) is a highly selective melatonin receptor type 1 and type 2 agonist,1,2 unlike nonprescription melatonin, which is nonselective for all three melatonin receptors.3 The U.S. Food and Drug Administration approved ramelteon 8-mg tablets for the treatment of insomnia characterized by difficulty with sleep onset. Ramelteon is the only prescription sleep aid not designated as a Schedule IV controlled substance.

NameStarting dosageDose formApproximate monthly cost*
Ramelteon (Rozerem)8 mg orally 30 minutes before going to bed8-mg tablets$82 (for 30 8-mg tablets)


No major safety issues have been identified with ramelteon. After one year of study participation, 3.1 percent of patients reported one or more serious adverse events, but less than 10 percent of those events were attributed to ramelteon.4 Ramelteon should not be used by patients taking fluvoxamine (Luvox), which can inhibit the metabolism of ramelteon, or by patients who have severe hepatic impairment. Use of ketoconazole (Nizoral) or fluconazole (Diflucan) increases blood levels of ramelteon, which may increase the risk of side effects or the therapeutic effect.5 Ramelteon does not have a significant additive effect when taken with alcohol. It has not been studied in children and therefore should not be used by adolescents or children. Ramelteon is pregnancy category C; it is not recommended for nursing mothers.


Ramelteon generally is well tolerated. During clinical studies, the discontinuation rate for ramelteon was 5 percent compared with 2 percent for placebo.5 Ramelteon does not produce residual “hangover” effects. In studies lasting 35 days, ramelteon did not cause rebound insomnia, and there was no evidence of withdrawal on discontinuation.5


Ramelteon has not been compared directly with other hypnotics or melatonin. The manufacturer conducted five unpublished placebo-controlled studies of effectiveness.5 In two studies using polysomnography to assess effectiveness, a faster onset of persistent sleep was found with ramelteon than with placebo. However, when patient evaluation (i.e., completion of postsleep questionnaires or sleep diaries) was used to assess effectiveness, a greater improvement with ramelteon than with placebo was found only in some studies.5 Patient evaluation is a more subjective measurement, but it also is more reflective of longer-term effects.

In patients with transient insomnia, improvements in sleep architecture with ramelteon were demonstrated using polysomnography, but evaluation with postsleep questionnaires showed no difference between ramelteon and placebo.5,6 Ramelteon has not been studied in patients with insomnia caused by depression or anxiety, in shift workers, or for the prevention or minimization of jet lag.


A one-month supply of ramelteon 8-mg tablets costs approximately $82. This is comparable to the cost of zaleplon (Sonata) and of zolpidem (Ambien) and is much higher than that of melatonin.


Ramelteon (8 mg) should be taken 30 minutes before going to bed, with or without food, although it is not recommended with or immediately after consumption of a high-fat meal. Fluvoxamine is the only drug that should not be used in combination with ramelteon.

Bottom Line

Ramelteon is safe and effective for decreasing the time to persistent sleep in patients with chronic insomnia. It does not have the potential for abuse or dependence that sedative hypnotics have and is not a controlled substance. No studies have compared ramelteon with other hypnotics or melatonin, and patient evaluation using postsleep questionnaires has not confirmed consistent benefit.

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

This series is coordinated by Allen F. Shaughnessy, PharmD, assistant medical editor.

A collection of STEPS published in AFP is available at

Continue Reading

More in AFP

Copyright © 2006 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.